New Open Trials with MultiCare
In collaboration with MultiCare Institute for Research & Innovation, we have opened enrollment for two new trials: the S2302 Pragmatica-Lung trial and the S2206 Hormone Receptor Positive HER2 Negative Clinical Stage II-III Breast Cancer trial.
Both studies are conducted by the National Cancer Institute through the Southwest Oncology Group (SWOG):
The Pragmatica-Lung Study (S2302)
The Pragmatica-Lung Study (S2302) is focused on evaluating the effectiveness of a two-drug combination non-chemotherapy treatment versus standard care for patients with advanced non-small cell lung cancer (NSCLC).
The Hormone Receptor Positive HER2 Negative Clinical Stage II-III Breast Cancer (S2206)
The Hormone Receptor Positive HER2 Negative Clinical Stage II-III Breast Cancer (S2206) trial compares breast cancer event-free survival among participants receiving standard neoadjuvant chemotherapy alone versus neoadjuvant chemotherapy concurrent with durvalumab.
What makes these trials unique is their user-friendly design, which simplifies participation for institutions and reduces barriers to patient eligibility. Our hope is that these studies serve two-fold: yielding valuable insights into lung and breast cancer research today, and establishing a precedent for the design, accessibility, and the diversity of patient populations for future trials.
In partnership with MultiCare, Northwest Medical Specialties, the Southwest Oncology Group (SWOG), and other medical institutions at the forefront of cancer care and research, we are collectively working towards a future where groundbreaking treatments and research are accessible to all who need it.
If you are interested in participating in one of our clinical trials, explore our open trials or contact us.
*Photos from MultiCare website.
